Compare
Pit 2–4 stocks against each other: U-Score, pillars, fundamentals, and normalized price history. Same universe, same methodology, one view.
| Metric | VIYASH Viyash Scientific Limited Pharma · Micro | THYROCARE Thyrocare Technologies Limited Pharma · Micro | NIDAN Nidan Laboratories And Healthcare Ltd. Pharma · SME | INVICTA Invicta Diagnostic Ltd. Pharma · SME |
|---|---|---|---|---|
| Final Score | 46 | 52 | 36 | 63 |
| Verdict | FAIR VALUE | FAIR VALUE | WATCHLIST | UNDERVALUED |
| Style | Financial Turnaround | Premium Compounder | WATCHLIST | Growth at Value |
| Piotroski | 8/9 | 8/9 | 6/9 | 8/9 |
| Valuation | 2/30 | 0/30 | 20/30 | 20/30 |
| Growth | 14/25 | 12/25 | 4/25 | 20/25 |
| Quality | 5/20 | 20/20 | 0/20 | 11/20 |
| Balance Sheet | 12/15 | 8/15 | 8/15 | 13/15 |
| Cash Flow | 8/10 | 8/10 | 8/10 | 1/10 |
| Price | ₹260 | ₹549 | ₹14 | ₹61.2 |
| P/E | 56.30 | 54.20 | 11.10 | 13.90 |
| P/B | 3.86 | 14.89 | 0.28 | 1.57 |
| ROE | 11.00% | 28.40% | 2.55% | 17.30% |
| ROCE | 19.00% | 35.40% | 5.99% | 22.80% |
| Debt / Equity | 0.17 | 0.09 | 0.16 | 0.00 |
| FCF Yield | 2.13% | 2.18% | 8.87% | — |
| Dividend Y | — | 1.70% | — | — |
| Altman Z | 6.22 | 9.35 | 2.54 | 8.16 |
| Promoter % | 61.31% | 60.92% | 57.04% | 66.70% |
| Mkt Cap (₹Cr) | 11247.00 | 8718.00 | 19.50 | 76.90 |
| Graham # | ₹78 | ₹92.08 | ₹35.05 | ₹62.14 |
| Fair PE | 42.0 | 23.5 | 5.4 | 42.0 |
| MoS % | -52.5% | -128.3% | -137.8% | +66.9% |
Normalized price (3-year, indexed to 100)
Higher line = better relative performance from startVIYASH124
THYROCARE56
NIDAN30
INVICTA71